Mandate

Vinge advises Brummer & Partners in connection with its investment in Saltside Technologies AB

January 29, 2015

Vinge advises Frontier PE (Cayman) L.P., a fond managed by Brummer & Partners, in connection with its investment in Saltside Technologies AB together with Kinnevik and Hillhouse Capital. Saltside Technologies AB operates the leading online horizontal classifieds platforms in three frontier markets through Bikroy (Bangladesh), Ikman (Sri Lanka) and Tonaton (Ghana). All three platforms are market leaders in terms of user base, engagement and monetization. The headquarters are located in Dubai and the group has over 200 employees to date. Frontier PE (Cayman) L.P. is a private equity fund based in Bangladesh and managed by Brummer & Partners, a leading European manager of hedge funds. Brummer & Partners manages 125 billion SEK on behalf of private persons, corporations and institutional investors.

The Vinge team advising Frontier PE (Cayman) L.P. includes partners Christina Kokko and Johan Larsson together with associates Maria Dahlin, Karin Virding and Nicklas Thorgerzon.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026